Compare Fastly Inc (FSLY) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Pfizer Inc — how do they compare? Fastly Inc trades at $28.5 (market cap $4.42B), while Pfizer Inc trades at $26.53 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 34.9× Fastly Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.
| FSLY | PFE | |
|---|---|---|
Market Cap | $4.42B | $154.18B |
Sector | Technology | Health |
52-Week High | $33.50 | $28.56 |
52-Week Low | $6.85 | $23.60 |
Enterprise Value | $4.48B | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $22.96, up 1.23% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $624 million in 2025, and the net loss margin improved to -19.5%. Recent news highlights security expansion and AI demand driving growth, with the stock surging 21% to $27.69 on August 10, 2026, per 24/7 Wall Street. The company raised its full-year 2026 outlook after Q2 results.
The outlook is positive with raised guidance and analyst consensus target of $28.25, but risks include persistent net losses, high debt, and competitive pressure. Investment opportunity lies in AI and security growth, yet profitability challenges and insider selling warrant caution for stock investors.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
